Neurological
Refine Search
Pharmaceutical
Eli Lilly saw its shares close down 6.6% at $744.91 yesterday, after it revealed forecast for sales at the JP Morgan Healthcare Conference. 15 January 2025
Pharmaceutical
Belgian drugmaker UCB has presented what it calls its ‘growth journey’ and the strategic priorities driving future success at the 43rd JP Morgan (JPM) Healthcare Conference in San Francisco, USA. 15 January 2025
Biotechnology
Dyno Therapeutics, a privately-held US genetic technologies company applying AI to enable in vivo gene delivery, has announced that Roche has exercised its option to license a novel capsid for use in a gene therapy program for an undisclosed neurological disease indication. 13 January 2025
Pharmaceutical
US radiopharmaceuticals-focused Lantheus Holdings today announced a definitive agreement to acquire Life Molecular Imaging. 13 January 2025
Pharmaceutical
Shares of USA-based Intra-Cellular Therapies leapt almost 36% to $128.85 in pre-marker activity today, as rumors of a takeover bid were confirmed. 13 January 2025
Pharmaceutical
AbbVie has announced a $3.5 billion non-cash impairment charge related to its potential schizophrenia treatment, emraclidine, following the drug's failure in Phase II trials last year. 13 January 2025
Biotechnology
Sage Therapeutics’ shares jumped over 45% to $8.09 in after-hours on Friday, after the company confirmed that biotech major Biogen has made a nonbinding proposal to acquire all of the outstanding shares of Sage not already owned by Biogen for $7.22 per share. 11 January 2025
Biotechnology
UK-based Alchemab Therapeutics, a biopharma seeking to identify and develop naturally occurring therapeutic antibodies from resilient individuals, has entered a collaboration with US pharma major Eli Lilly to discover novel therapeutic candidates to treat amyotrophic lateral sclerosis (ALS). 9 January 2025
Pharmaceutical
Italy-based Newron Pharmaceuticals (SIX: NWRN, XETRA: NP5), a biopharma developing therapies for diseases of the central and peripheral nervous system, has announced a deal with South Korea’s Myung In Pharm. 9 January 2025
Biotechnology
Cambridge, USA-based biotech Sunbird Bio, which is developing proprietary blood-based technologies to improve diagnosis and treatment of neurological disorders and early-stage cancer, today announced the appointment of DR Richard Batrla, as chief medical officer. 9 January 2025
Pharmaceutical
Calico Life Sciences, a biotech founded by Alphabet and Arthur Levinson focused on the biology of aging and age-related diseases, has announced a setback. 8 January 2025
Biotechnology
Capsida Biotherapeutics yesterday revealed US pharma major AbbVie has exercised an option for the first neurodegenerative disease program under their ongoing collaboration. 8 January 2025
Biotechnology
The past year has been a very busy one for privately-held Dewpoint Therapeutics, a Boston firm founded in 2018 that focuses on the application of biomolecular condensate biology towards the development of a new generation of therapeutics to address diseases of high unmet need. 7 January 2025
Pharmaceutical
A late-stage trial failure has dented Denali Therapeutics stock, with an announcement Monday revealing the HEALEY ALS study missed all endpoints. 7 January 2025
Biotechnology
Among significant news in a holiday spattered week, Dutch biotech argenx gained another approval in Japan for its Vyvdura (efgartigimod alfa and hyaluronidase-qvf), this time for adult patients with demyelinating polyneuropathy (CIDP). Axsome Therapeutics released mixed results from the completed Phase III program for its Alzheimer’s agitation candidate AXS-05 (dextromethorphan-bupropion and aminoketone). Also, Sangamo plunged on the news that Pfizer had unexpectedly pulled out of their deal on the development of hemophilia A candidate giroctocogene fitelparvovec (giro-vec). 5 January 2025
Pharmaceutical
Massachusetts, USA-based based brain disease biotech Neumora Therapeutics shares tumbled 81.4% to 1.97 after it revealed that its experimental depression treatment failed in the first of three studies planned by the biotech company. 3 January 2025
Pharmaceutical
US CNS specialist Axsome Therapeutics yesterday announced the completion of its Phase III clinical program evaluating AXS-05 (dextromethorphan-bupropion). 31 December 2024
Pharmaceutical
US pharma major Eli Lilly today announced the US Food and Drug Administration (FDA) approved Zepbound its (tirzepatide) as the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. 23 December 2024
Pharmaceutical
Among significant research news last week, UK drug developer PureTech released positive new Phase IIb data on its deupirfenidone in idiopathic pulmonary fibrosis. France’s Sanofi and Israel-based Teva Pharmaceutical Industries announced encouraging new Phase IIb data for their duvakitug in inflammatory bowel disease. Meanwhile, Vertex Pharmaceuticals released Phase II results for its investigational sciatica treatment suzetrigine that failed to impress. Also of note, AbbVie announced strong Phase III results of tavapadon in early Parkinson’s disease. 22 December 2024
Biotechnology
Astellas Pharma has struck a licensing agreement with Sangamo Therapeutics to make use of its neurotropic adeno-associated virus capsid, STAC-BBB. 20 December 2024
Pharmaceutical
The European Medicines’ (EMA) human medicines committee (CHMP) has recommended seven novel medicines for approval at its July 2025 meeting. 25 July 2025
Pharmaceutical
Semaglutide, a GLP-1R agonist developed by Denmark’s Novo Nordisk as Ozempic, initially for type 2 diabetes, and marketed under the trade name Wegovy for obesity, is emerging as a promising candidate for neurological conditions. 25 July 2025
Pharmaceutical
Privately-held Spanish CNS specialist Minoryx Therapeutics and Germany’s Neuraxpharm Group today announced that the marketing authorization application (MAA) for Minoryx’ lead candidate Nezglyal (leriglitazone) has been submitted to the European Medicines Agency (EMA) for the treatment of pediatric and adult male patients with cerebral adrenoleukodystrophy (cALD). 23 July 2025
Pharmaceutical
French pharma Ipsen (Euronext: IPN) today announced the following changes to its executive committee: 23 July 2025
Pharmaceutical
Neuraxpharm Group, a privately-held German specialty pharma focused on central nervous system (CNS) disorders, today announced the launch of a new affiliate, Neuraxpharm Australia, led by newly appointed head of commercial, Avendran Naidu, as the company continues to expand globally. 22 July 2025
Pharmaceutical
Ireland-based Alkermes has announced positive topline results from the randomized double-blind treatment period of the Vibrance-1 Phase II study evaluating alixorexton in patients with narcolepsy type 1 (NT1). 22 July 2025
Biotechnology
US biotech major Biogen has announced that it intends to invest an additional $2 billion in its existing manufacturing footprint in North Carolina’s Research Triangle Park (RTP). 21 July 2025
Pharmaceutical
Sweden’s OncoZenge has chosen Meribel Pharma Solutions—formerly Recipharm—to be the contract development and manufacturing organization (CDMO) for its BupiZenge Phase III project. 21 July 2025
Pharmaceutical
The Psychopharmacologic Drugs Advisory Committee (PDAC) of the US Food and Drug Administration (FDA) met to discuss the supplemental New Drug Application (sNDA) of Rexulti (brexpiprazole) in combination with sertraline for the treatment of adults with post-traumatic stress disorder (PTSD). 21 July 2025
Biotechnology
The European Commission granted conditional marketing authorization for Ezmekly (mirdametinib) for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in pediatric and adult patients with neurofibromatosis type 1 (NF1) aged two years and above. 19 July 2025
Pharmaceutical
A major collaboration between the Allen Institute and the Aligning Science Across Parkinson’s (ASAP) initiative is set to transform neurodegenerative disease research by integrating Parkinson’s-specific brain cell data into the Allen Brain Cell (ABC) Atlas. The effort is expected to amplify understanding of the cellular mechanisms driving Parkinson’s and other related conditions, offering scientists a high-resolution view into previously inaccessible datasets. 17 July 2025
Pharmaceutical
Swiss pharma giant Novartis this morning reported second quarter 2025 financial results, showing that net sales were $14.1 billion (+12%, +11% cc), with volume contributing 12 percentage points to growth. This was slightly better than the consensus estimate of $14.02 billion. 17 July 2025
Pharmaceutical
Bayer is giving chief executive Bill Anderson more time to deliver on his ambitious efforts to reshape the German group, extending his contract by three years to March 2029. The move signals strong support from the company’s supervisory board, which voted unanimously in favor of the renewal. 17 July 2025
Pharmaceutical
Shares in US healthcare conglomerate Johnson & Johnson rose by 6% during Wednesday morning’s trading after the presentation of its second-quarter financial results and latest guidance for 2025. 16 July 2025
Biotechnology
Japanese drugmaker JCR Pharmaceuticals has entered into a joint collaboration, option and license agreement with US biotech Acumen Pharmaceuticals to develop a novel therapeutic candidate for the treatment of Alzheimer’s disease (AD), enabled by JCR’s proprietary blood-brain barrier (BBB)-penetrating technology platform, J-Brain Cargo 16 July 2025
Biotechnology
The USA's Institute for Clinical and Economic Review (ICER) has released a Final Evidence Report assessing the comparative clinical effectiveness and value of Sanofi’s tolebrutinib for the treatment of secondary progressive multiple sclerosis (SPMS). 15 July 2025
Biotechnology
Swiss clinical-stage CNS disease specialist Synendos Therapeutics has named Dr George Garibaldi as its chief medical officer (CMO). 15 July 2025
Pharmaceutical
Japan’s largest pharma company Takeda today announced that all primary and secondary endpoints were met in two Phase III randomized, double-blind, placebo-controlled studies of oveporexton (TAK-861). 14 July 2025
Pharmaceutical
South Korean biotech Illimis Therapeutics has raised 58 billion won ($42 million) in a series B round to advance its GAIA platform into the preclinical stage and expand its drug development programs targeting Alzheimer’s disease and immune disorders. 14 July 2025
Biotechnology
Japanese drugmaker Chugai Pharmaceutical has entered into a joint research and license agreement to develop novel therapies for age-related diseases with Singapore-based biotech Gero. 12 July 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze